Mouse Models of Colon Cancer

Gastroenterology

Volumn 136, Issue 3, 2009, Pages 780-798

  Taketo, Makoto Mark ^a   Edelmann, Winfried ^b  

^a KYOTO UNIVERSITY   (Japan)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APC PROTEIN; AXIN; BETA CATENIN; BUB1 RELATED PROTEIN; CELECOXIB; CYCLIN DEPENDENT KINASE INHIBITOR 1A; CYCLIN DEPENDENT KINASE INHIBITOR 1B; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; DNA METHYLTRANSFERASE 1; GLYCOGEN SYNTHASE KINASE 3BETA; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 6; MATRILYSIN; METHYL CPG BINDING PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; PROSTAGLANDIN D SYNTHASE; PROSTAGLANDIN E SYNTHASE; PROTEIN MLH1; PROTEIN MSH2; PROTEIN MSH6; PROTEIN MUTL; PROTEIN P53; ROFECOXIB; SMAD4 PROTEIN; T CELL FACTOR PROTEIN; TRANSCRIPTION FACTOR CDX2; WNT PROTEIN;

ADENOMATOUS POLYP; ANIMAL MODEL; APC GENE; ARACHIDONIC ACID METABOLISM; CARCINOGENESIS; CD4+ CD25+ T LYMPHOCYTE; COLON CANCER; COLORECTAL CANCER; DIET; DNA DAMAGE; ENTERITIS; FAMILIAL CANCER; GENE MUTATION; HISTOPATHOLOGY; KNOCKOUT MOUSE; LYMPHOMA; METASTASIS; MISMATCH REPAIR; MOUSE; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; SKIN TUMOR; TUMOR SUPPRESSOR GENE; TUMOR XENOGRAFT;

EID: 60449086469     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.gastro.2008.12.049     Document Type: Review

References (196)

1. Groden J., Thliveris A., Samowitz W., et al. Identification and characterization of the familial adenomatous polyposis coli gene. Cell 66 (1991) 589-600
2. Kinzler K.W., Nilbert M.C., Vogelstein B., et al. Identification of a gene located at chromosome 5q21 that is mutated in colorectal cancers. Science 251 (1991) 1366-1370
3. Polakis P. The oncogenic activation of beta-catenin. Curr Opin Genet Dev 9 (1999) 15-21
4. -/- colon carcinoma. Science 275 (1997) 1784-1787
5. Δ716 knockout mice. Cancer Res 57 (1997) 1644-1649
6. Moser A.R., Pitot H.C., and Dove W.F. A dominant mutation that predisposes to multiple intestinal neoplasia in the mouse. Science 247 (1990) 322-324
7. Su L.K., Kinzler K.W., Vogelstein B., et al. Multiple intestinal neoplasia caused by a mutation in the murine homolog of the APC gene. Science 256 (1992) 668-670
8. Fodde R., Edelmann W., Yang K., et al. A targeted chain-termination mutation in the mouse Apc gene results in multiple tumors. Proc Natl Acad Sci U S A 91 (1994) 8969-8973
9. Oshima M., Oshima H., Kitagawa K., et al. Loss of Apc heterozygosity and abnormal tissue building in nascent intestinal polyps in mice carrying a truncated Apc gene. Proc Natl Acad Sci U S A 92 (1995) 4482-4486
10. +/- compound mutant mice. Nat Genet 35 (2003) 323-330
11. Munemitsu S., Souza B., Müller O., et al. The APC gene product associates with microtubules in vivo and promotes their assembly in vitro. Cancer Res 54 (1994) 3676-3681
12. Smith K.J., Levy D.B., Maupin P., et al. Wild-type but not mutant APC associates with the microtubule cytoskeleton. Cancer Res 54 (1994) 3672-3675
13. Nathke I.S., Adams C.L., Polakis P., et al. The adenomatous polyposis coli tumor suppressor protein localizes to plasma membrane sites involved in active cell migration. J Cell Biol 134 (1996) 165-178
14. Mimori-Kiyosue Y., Shiina N., and Tsukita S. Adenomatous polyposis coli (APC) protein moves along microtubules and concentrates at their growing ends in epithelial cells. J Cell Biol 148 (2000) 505-517
15. Rosin-Arbesfeld R., Ihrke G., and Bienz M. Actin-dependent membrane association of the APC tumor suppressor in polarized mammalian epithelial cells. EMBO J 20 (2001) 5929-5939
16. Kawasaki Y., Senda T., Ishidate T., et al. Asef, a link between the tumor suppressor APC and G-protein signaling. Science 289 (2000) 1194-1197
17. Kawasaki Y., and Akiyama T. Mutated APC and Asef are involved in the migration of colorectal tumour cells. Nat Cell Biol 5 (2003) 211-215
18. Watanabe T., Wang S., Noritake J., et al. Interaction with IQGAP1 links APC to Rac1, Cdc42, and actin filaments during cell polarization and migration. Dev Cell 7 (2004) 871-883
19. Kawasaki Y., Sagara M., Shibata Y., et al. Identification and characterization of Asef2, a guanine-nucleotide exchange factor specific for Rac1 and Cdc42. Oncogene 26 (2007) 7620-7627
20. Colnot S., Niwa-Kawakita M., Hamard G., et al. Colorectal cancers in a new mouse model of familial adenomatous polyposis: influence of genetic and environmental modifiers. Lab Invest 84 (2004) 1619-1630
21. Min/+ mouse model of intestinal tumorigenesis. Blood 103 (2004) 1050-1058
22. Min/+ mice. Cancer Res 65 (2005) 3998-4004
23. Benhamouche S., Decaens T., Godard C., et al. Apc tumor suppressor gene is the "zonation-keeper" of mouse. Dev Cell 10 (2006) 759-770
24. Min/+ mice. Am J Physiol Regul Integr Comp Physiol 294 (2008) R393-R401
25. Taketo M.M. Cyclooxygenase-2 inhibitors in tumorigenesis (Part I). J Natl Cancer Inst 90 (1998) 1529-1536
26. Taketo M.M. Cyclooxygenase-2 inhibitors in tumorigenesis (Part II). J Natl Cancer Inst 90 (1998) 1609-1620
27. Chulada P.C., Thompson M.B., Mahler J.F., et al. Genetic disruption of Ptgs-1, as well as of Ptgs-2, reduces intestinal tumorigenesis in Min mice. Cancer Res 60 (2000) 4705-4708
28. Δ716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell 87 (1996) 803-809
29. Δ716 mouse by rofecoxib, a specific cyclooxygenase-2 inhibitor. Cancer Res 61 (2001) 1733-1740
30. Steinbach G., Lynch P.M., Phillips R.K.S., et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 342 (2000) 1946-1952
31. Takeda H., Sonoshita M., Sugihara K., et al. Cooperation of cyclooxygenase 1 and cyclooxygenase 2 in intestinal polyposis. Cancer Res 63 (2003) 4872-4877
32. Solomon S.D., McMurray J.J.V., Pfeffer M.A., et al. Cardiovascular risk assessment with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 352 (2005) 1071-1080
33. Bresalier R.S., Sandler R.S., Quan H., et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 352 (2005) 1092-1102
34. Δ716 knockout mice. Nat Med 7 (2001) 1048-1051
35. Sheng H., Shao J., Washington M.K., et al. Prostaglandin E2 increases growth and motility of colorectal carcinoma cells. J Biol Chem 276 (2001) 18075-18081
36. Cherukuri D.P., Chen X.B., Goulet A.C., et al. The EP4 receptor antagonist, L-161,982, blocks prostaglandin E2-induced signal transduction and cell proliferation in HCA-7 colon cancer cells. Exp Cell Res 313 (2007) 2969-2979
37. Yang L., Huang Y., Porta R., et al. Host and direct antitumor effects and profound reduction in tumor metastasis with selective EP4 antagonism. Cancer Res 66 (2006) 9665-9672
38. de Leng W.W., Westerman A.M., de Rooij F.W., et al. Cyclooxygenase 2 expression and molecular alterations in Peutz-Jeghers hamartomas and carcinomas. Clin Cancer Res 9 (2003) 3065-3072
39. Takeda H., Miyoshi H., Tamai Y., et al. Simultaneous expression of COX-2 and mPGES-1 in mouse gastrointestinal hamartomas. Br J Cancer 90 (2004) 701-704
40. DuBois R.N. New agents for cancer prevention. J Natl Cancer Inst 94 (2002) 1732-1733
41. Castellone M.D., Teramoto H., Williams B.O., et al. Prostaglandin E2 promotes coon cancer cell growth through a novel Gs-axin-b-catenin signaling axis. Science 310 (2005) 1504-1510
42. Min/+ compound mutant mice is linked to premature separation of sister chromatids and enhanced genomic instability. Proc Natl Acad Sci U S A 102 (2005) 4365-4370
43. Δ716 knockout mice. Carcinogenesis 16 (1995) 2605-2607
44. Δ716 knockout mice. Carcinogenesis 18 (1997) 1863-1865
45. Yang K., Edelman W., Fan K., et al. Dietary modulation of carcinoma development in a mouse model for human familial adenomatous polyposis. Cancer Res 58 (1998) 5713-5717
46. Min mice through different mechanisms. Cancer Res 63 (2003) 1752-1755
47. Min/+ mice. J Appl Physiol 98 (2005) 2219-2225
48. Fenton J.I., and Hord N.G. Stage matters: choosing relevant model systems to address hypotheses in diet and cancer chemoprevention research. Carcinogenesis 27 (2006) 893-902
49. Romagnolo B., Berrebi D., Saadi-Keddoucci S., et al. Intestinal dysplasia and adenoma in transgenic mice after overexpression of an activated β-catenin. Cancer Res 59 (1999) 3875-3879
50. Harada N., Tamai Y., Ishikawa T., et al. Intestinal polyposis in mice with a dominant stable mutation of the β-catenin gene. EMBO J 18 (1999) 5931-5942
51. Gounari F., Signoretti S., Bronson R., et al. Stabilization of β-catenin induces lesions reminiscent of prostatic intraepithelial neoplasia, but terminal squamous transdifferentiation of other secretory epithelia. Oncogene 21 (2002) 4099-4107
52. Lickert H., Domon C., Huls G., et al. Wnt/β-catenin signaling regulates the expression of the homeobox gene Cdx1 in embryonic intestine. Development 127 (2000) 3805-3813
53. Gounaris F., Aifantis I., Khazaie K., et al. Somatic activation of β-catenin bypasses pre-TCR signaling and TCR selection in thymocyte development. Nat Immunol 2 (2001) 863-869
54. Taketo M.M. Wnt signaling and gastrointestinal tumorigenesis in mouse models. Oncogene 25 (2006) 7522-7530
55. Takaku K., Oshima M., Miyoshi H., et al. Intestinal tumorigenesis in compound mutant mice of both Dpc4 (Smad4) and Apc genes. Cell 92 (1998) 645-656
56. Munoz N.M., Upton M., Rojas A., et al. Transforming growth factor beta receptor type II inactivation induces the malignant transformation of intestinal neoplasms initiated by Apc mutation. Cancer Res 66 (2006) 9837-9844
57. Kitamura T., Kometani K., Hashida H., et al. SMAD4-deficient intestinal tumors recruit CCR1+ myeloid cells that promote invasion. Nat Genet 39 (2007) 467-475
58. Kitamura T., and Taketo M.M. Keeping out the bad guys: gateway to cellular target therapy. Cancer Res 67 (2007) 10099-10102
59. Coussens L.M., Fingleton B., and Matrisian L.M. Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 295 (2002) 2387-2392
60. Gounaris E., Erdman S.E., Restaino C., et al. Mast cells are an essential hematopoietic component for polyp development. Proc Natl Acad Sci U S A 104 (2007) 19977-19982
61. min/+ mouse: roles of osteopoitin. Carcinogenesis 28 (2007) 2476-2483
62. Petrova T.V., Nykänen A., Norrimén C., et al. Transcription factor PROX1 induces colon cancer progression by promoting the transition from benign to highly dysplastic phenotype. Cancer Cell 13 (2008) 407-419
63. Lynch H.T., and Smyrk T. Hereditary nonpolyposis colorectal cancer (Lynch syndrome). An updated review. Cancer 78 (1996) 1149-1167
64. Peltomaki P. Role of DNA mismatch repair defects in the pathogenesis of human cancer. J Clin Oncol 21 (2003) 1174-1179
65. Vasen H.F., and Boland C.R. Progress in genetic testing, classification, and identification of Lynch syndrome. JAMA 293 (2005) 2028-2030
66. Rustgi A.K. The genetics of hereditary colon cancer. Genes Dev 21 (2007) 2525-2538
67. Vasen H.F., Mecklin J.P., Khan P.M., et al. The International Collaborative Group on Hereditary Non-Polyposis Colorectal Cancer (ICG-HNPCC). Dis Colon Rectum 34 (1991) 424-425
68. Vasen H.F., Watson P., Mecklin J.P., et al. New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC. Gastroenterology 116 (1999) 1453-1456
69. Aaltonen L.A., Peltomaki P., Leach F.S., et al. Clues to the pathogenesis of familial colorectal cancer. Science 260 (1993) 812-816
70. Ionov Y., Peinado M.A., Malkhosyan S., et al. Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis. Nature 363 (1993) 558-5561
71. Umar A. Lynch syndrome (HNPCC) and microsatellite instability. Dis Markers 20 (2004) 179-180
72. Iyer R.R., Pluciennik A., Burdett V., et al. DNA mismatch repair: functions and mechanisms. Chem Rev 106 (2006) 302-323
73. Kolodner R.D., and Marsischky G.T. Eukaryotic DNA mismatch repair. Curr Opin Genet Dev 9 (1999) 89-96
74. Edelmann W., Umar A., Yang K., et al. The DNA mismatch repair genes Msh3 and Msh6 cooperate in intestinal tumor suppression. Cancer Res 60 (2000) 803-807
75. Genschel J., Littman S.J., Drummond J.T., et al. Isolation of MutSbeta from human cells and comparison of the mismatch repair specificities of MutSbeta and MutSalpha. J Biol Chem 273 (1998) 19895-19901
76. Marsischky G.T., Filosi N., Kane M.F., et al. Redundancy of Saccharomyces cerevisiae MSH3 and MSH6 in MSH2-dependent mismatch repair. Genes Dev 10 (1996) 407-420
77. Umar A., Risinger J.I., Glaab W.E., et al. Functional overlap in mismatch repair by human MSH3 and MSH6. Genetics 148 (1998) 1637-1646
78. de Vries S.S., Baart E.B., Dekker M., et al. Mouse MutS-like protein Msh5 is required for proper chromosome synapsis in male and female meiosis. Genes Dev 13 (1999) 523-531
79. Edelmann W., Cohen P.E., Kneitz B., et al. Mammalian MutS homologue 5 is required for chromosome pairing in meiosis. Nat Genet 21 (1999) 123-127
80. Kneitz B., Cohen P.E., Avdievich E., et al. MutS homolog 4 localization to meiotic chromosomes is required for chromosome pairing during meiosis in male and female mice. Genes Dev 14 (2000) 1085-1097
81. Buermeyer A.B., Deschênes S.M., Baker S.M., et al. Mammalian mismatch repair. Annu Rev Genet 33 (1999) 533-564
82. Blackwell L.J., Martik D., Bjornson K.P., et al. Nucleotide-promoted release of hMutSalpha from heteroduplex DNA is consistent with an ATP-dependent translocation mechanism. J Biol Chem 273 (1998) 32055-32062
83. Fishel R. Mismatch repair, molecular switches, and signal transduction. Genes Dev 12 (1998) 2096-2101
84. Junop M.S., Obmolova G., Rausch K., et al. Composite active site of an ABC ATPase: MutS uses ATP to verify mismatch recognition and authorize DNA repair. Mol Cell 7 (2001) 1-12
85. Sacho E.J., Kadyrov F.A., Modrich P., et al. Direct visualization of asymmetric adenine-nucleotide-induced conformational changes in MutL alpha. Mol Cell 29 (2008) 112-121
86. Fang W.H., and Modrich P. Human strand-specific mismatch repair occurs by a bidirectional mechanism similar to that of the bacterial reaction. J Biol Chem 268 (1993) 11838-11844
87. Wang H., and Hays J.B. Mismatch repair in human nuclear extracts. Time courses and ATP requirements for kinetically distinguishable steps leading to tightly controlled 5′ to 3′ and aphidicolin-sensitive 3′ to 5′ mispair-provoked excision. J Biol Chem 277 (2002) 26143-26148
88. Genschel J., and Modrich P. Mechanism of 5′-directed excision in human mismatch repair. Mol Cell 12 (2003) 1077-1086
89. Constantin N., Dzantiev L., Kadyrov F.A., et al. Human mismatch repair: reconstitution of a nick-directed bidirectional reaction. J Biol Chem 280 (2005) 39752-39761
90. Zhang Y., Yuan F., Presnell S.R., et al. Reconstitution of 5′-directed human mismatch repair in a purified system. Cell 122 (2005) 693-705
91. Kadyrov F.A., Dzantiev L., Constantin N., et al. Endonucleolytic function of MutLalpha in human mismatch repair. Cell 126 (2006) 297-308
92. Wei K., Clark A.B., Wong E., et al. Inactivation of Exonuclease 1 in mice results in DNA mismatch repair defects, increased cancer susceptibility, and male and female sterility. Genes Dev 17 (2003) 603-614
93. Fishel R. The selection for mismatch repair defects in hereditary nonpolyposis colorectal cancer: revising the mutator hypothesis. Cancer Res 61 (2001) 7369-7374
94. Stojic L., Brun R., and Jiricny J. Mismatch repair and DNA damage signalling. DNA Repair (Amst) 3 (2004) 1091-1101
95. Li G.M. Mechanisms and functions of DNA mismatch repair. Cell Res 18 (2008) 85-98
96. Karran P. Mechanisms of tolerance to DNA damaging therapeutic drugs. Carcinogenesis 22 (2001) 1931-1937
97. Kat A., Thilly W.G., Fang W.H., et al. An alkylation-tolerant, mutator human cell line is deficient in strand-specific mismatch repair. Proc Natl Acad Sci U S A 90 (1993) 6424-6428
98. Stojic L., Mojas N., Cejka P., et al. Mismatch repair-dependent G2 checkpoint induced by low doses of SN1 type methylating agents requires the ATR kinase. Genes Dev 18 (2004) 1331-1344
99. Adamson A.W., Beardsley D.I., Kim W.J., et al. Methylator-induced, mismatch repair-dependent G2 arrest is activated through Chk1 and Chk2. Mol Biol Cell 16 (2005) 1513-1526
100. Caporali S., Falcinelli S., Starace G., et al. DNA damage induced by temozolomide signals to both ATM and ATR: role of the mismatch repair system. Mol Pharmacol 66 (2004) 478-491
101. Yan T., Desai A.B., Jacobberger J.W., et al. CHK1 and CHK2 are differentially involved in mismatch repair-mediated 6-thioguanine-induced cell cycle checkpoint responses. Mol Cancer Ther 3 (2004) 1147-1157
102. Yoshioka K., Yoshioka Y., and Hsieh P. ATR kinase activation mediated by MutSalpha and MutLalpha in response to cytotoxic O6-methylguanine adducts. Mol Cell 22 (2006) 501-510
103. Peled J.U., Kuang F.L., Iglesias-Ussel M.D., et al. The biochemistry of somatic hypermutation. Annu Rev Immunol 26 (2008) 481-511
104. Kolas N.K., and Cohen P.E. Novel and diverse functions of the DNA mismatch repair family in mammalian meiosis and recombination. Cytogenet Genome Res 107 (2004) 216-231
105. McMurray C.T. Hijacking of the mismatch repair system to cause CAG expansion and cell death in neurodegenerative disease. DNA Repair (Amst) 7 (2008) 1121-1134
106. Edelmann L., and Edelmann W. Loss of DNA mismatch repair function and cancer predisposition in the mouse: animal models for human hereditary nonpolyposis colorectal cancer. Am J Med Genet C Semin Med Genet 129C (2004) 91-99
107. Felton K.E., Gilchrist D.M., and Andrew S.E. Constitutive deficiency in DNA mismatch repair. Clin Genet 71 (2007) 483-498
108. de Wind N., Dekker M., Berns A., et al. Inactivation of the mouse Msh2 gene results in mismatch repair deficiency, methylation tolerance, hyperrecombination, and predisposition to cancer. Cell 82 (1995) 321-330
109. Reitmair A.H., Redston M., Cai J.C., et al. Spontaneous intestinal carcinomas and skin neoplasms in Msh2-deficient mice. Cancer Res 56 (1996) 3842-3849
110. Smits R., Hofland N., Edelmann W., et al. Somatic apc mutations are selected upon their capacity to inactivate the beta-catenin downregulating activity. Genes Chromosomes Cancer 29 (2000) 229-239
111. de Wind N., Dekker M., van Rossum A., et al. Mouse models for hereditary nonpolyposis colorectal cancer. Cancer Res 58 (1998) 248-255
112. Hinoi T., Akyol A., Theisen B.K., et al. Mouse model of colonic adenoma-carcinoma progression based on somatic Apc inactivation. Cancer Res 67 (2007) 9721-9730
113. Edelmann W., Yang K., Umar A., et al. Mutation in the mismatch repair gene Msh6 causes cancer susceptibility. Cell 91 (1997) 467-477
114. Kolodner R.D., Tytell J.D., Schmeits J.L., et al. Germ-line msh6 mutations in colorectal cancer families. Cancer Res 59 (1999) 5068-5074
115. de Wind N., Dekker M., Claij N., et al. HNPCC-like cancer predisposition in mice through simultaneous loss of Msh3 and Msh6 mismatch-repair protein functions. Nat Genet 23 (1999) 359-362
116. Wijnen J., de Leeuw W., Vasen H., et al. Familial endometrial cancer in female carriers of MSH6 germline mutations. Nat Genet 23 (1999) 142-144
117. Baker S.M., Plug A.W., Prolla T.A., et al. Involvement of mouse Mlh1 in DNA mismatch repair and meiotic crossing over. Nat Genet 13 (1996) 336-342
118. Edelmann W., Cohen P.E., Kane M., et al. Meiotic pachytene arrest in MLH1-deficient mice. Cell 85 (1996) 1125-1134
119. Prolla T.A., Baker S.M., Harris A.C., et al. Tumour susceptibility and spontaneous mutation in mice deficient in Mlh1, Pms1 and Pms2 DNA mismatch repair. Nat Genet 18 (1998) 276-279
120. Edelmann W., Yang K., Kuraguchi M., et al. Tumorigenesis in Mlh1 and Mlh1/Apc1638N mutant mice. Cancer Res 59 (1999) 1301-1307
121. Baker S.M., Bronner C.E., Zhang I., et al. Male mice defective in the DNA mismatch repair gene PMS2 exhibit abnormal chromosome synapsis in meiosis. Cell 82 (1995) 309-320
122. Senter L., Clendenning M., Sotamaa K., et al. The clinical phenotype of Lynch syndrome because of germ-line PMS2 mutations. Gastroenterology 135 (2008) 419-428
123. Miller A.J., Dudley S.D., Tsao J.L., et al. Tractable Cre-lox system for stochastic alteration of genes in mice. Nat Methods 5 (2008) 227-229
124. Chen P.C., Dudley S., Hagen W., et al. Contributions by MutL homologues Mlh3 and Pms2 to DNA mismatch repair and tumor suppression in the mouse. Cancer Res 65 (2005) 8662-8670
125. Wu Y., Berends M.J., Post J.G., et al. Germline mutations of EXO1 gene in patients with hereditary nonpolyposis colorectal cancer (HNPCC) and atypical HNPCC forms. Gastroenterology 120 (2001) 1580-1587
126. (1638N) mice with Exo1 and Fen1 deficiencies. Oncogene 26 (2007) 6297-6306
127. Reitmair A.H., Cai J.C., Bjerknes M., et al. MSH2 deficiency contributes to accelerated APC-mediated intestinal tumorigenesis. Cancer Res 56 (1996) 2922-2926
128. -/-; Min mice. Cancer Res 58 (1998) 1087-1089
129. 1638N mice define the roles of MSH3 and MSH6 in DNA repair and intestinal tumorigenesis. Cancer Res 61 (2001) 7934-7942
130. Toft N.J., Curtis L.J., Sansom O.J., et al. Heterozygosity for p53 promotes microsatellite instability and tumorigenesis on a Msh2 deficient background. Oncogene 21 (2002) 6299-6306
131. Young L.C., Keuling A.M., Lai R., et al. The associated contributions of p53 and the DNA mismatch repair protein Msh6 to spontaneous tumorigenesis. Carcinogenesis 28 (2007) 2131-2138
132. Kawate H., Sakumi K., Tsuzuki T., et al. Separation of killing and tumorigenic effects of an alkylating agent in mice defective in two of the DNA repair genes. Proc Natl Acad Sci U S A 95 (1998) 5116-5120
133. Qin X., Liu L., and Gerson S.L. Mice defective in the DNA mismatch gene PMS2 are hypersensitive to MNU induced thymic lymphoma and are partially protected by transgenic expression of human MGMT. Oncogene 18 (1999) 4394-4400
134. Colussi C., Fiumicino S., Giuliani A., et al. 1,2-Dimethylhydrazine-induced colon carcinoma and lymphoma in msh2(-/-) mice. J Natl Cancer Inst 93 (2001) 1534-1540
135. Toft N.J., Winton D.J., Kelly J., et al. Msh2 status modulates both apoptosis and mutation frequency in the murine small intestine. Proc Natl Acad Sci U S A 96 (1999) 3911-3915
136. Wu T.H., and Marinus M.G. Dominant negative mutator mutations in the mutS gene of Escherichia coli. J Bacteriol 176 (1994) 5393-5400
137. Drotschmann K., Clark A.B., Tran H.T., et al. Mutator phenotypes of yeast strains heterozygous for mutations in the MSH2 gene. Proc Natl Acad Sci U S A 96 (1999) 2970-2975
138. Peltomaki P., and Vasen H. Mutations associated with HNPCC predisposition-update of ICG-HNPCC/INSiGHT mutation database. Dis Markers 20 (2004) 269-276
139. Lin D.P., Wang Y., Scherer S.J., et al. An Msh2 point mutation uncouples DNA mismatch repair and apoptosis. Cancer Res 64 (2004) 517-522
140. Hess M.T., Gupta R.D., and Kolodner R.D. Dominant Saccharomyces cerevisiae msh6 mutations cause increased mispair binding and decreased dissociation from mispairs by Msh2-Msh6 in the presence of ATP. J Biol Chem 277 (2002) 25545-25553
141. Hess M.T., Mendillo M.L., Mazur D.J., et al. Biochemical basis for dominant mutations in the Saccharomyces cerevisiae MSH6 gene. Proc Natl Acad Sci U S A 103 (2006) 558-563
142. Yang G., Scherer S.J., Shell S.S., et al. Dominant effects of an Msh6 missense mutation on DNA repair and cancer susceptibility. Cancer Cell 6 (2004) 139-150
143. Berends M.J., Wu Y., Sijmons R.H., et al. Molecular and clinical characteristics of MSH6 variants: an analysis of 25 index carriers of a germline variant. Am J Hum Genet 70 (2002) 26-37
144. Avdievich E., Reiss C., Scherer S.J., et al. Distinct effects of the recurrent Mlh1G67R mutation on MMR functions, cancer, and meiosis. Proc Natl Acad Sci U S A 105 (2008) 4247-4252
145. Burstein E., and Fearon E.R. Colitis and cancer: a tale of inflammatory cells and their cytokines. J Clin Invest 118 (2008) 464-467
146. Sadlack B., Merz H., Schorle H., et al. Ulcerative colitis-like disease in mice with a disrupted interleukin-2 gene. Cell 75 (1993) 253-261
147. Kuhn R., Lohler J., Rennick D., et al. Interleukin-10-deficient mice develop chronic enterocolitis. Cell 75 (1993) 263-274
148. Berg D.J., Davidson N., Kuhn R., et al. Enterocolitis and colon cancer in interleukin-10-deficient mice are associated with aberrant cytokine production and CD4(+) TH1-like responses. J Clin Invest 98 (1996) 1010-1020
149. Simpson S.J., Mizoguchi E., Allen D., et al. Evidence that CD4+, but not CD8+ T cells are responsible for murine interleukin-2-deficient colitis. Eur J Immunol 25 (1995) 2618-2625
150. Shah S.A., Simpson S.J., Brown L.F., et al. Development of colonic adenocarcinomas in a mouse model of ulcerative colitis. Inflamm Bowel Dis 4 (1998) 196-202
151. Schultz M., Tonkonogy S.L., Sellon R.K., et al. IL-2-deficient mice raised under germfree conditions develop delayed mild focal intestinal inflammation. Am J Physiol 276 (1999) G1461-G1472
152. Sellon R.K., Tonkonogy S., Schultz M., et al. Resident enteric bacteria are necessary for development of spontaneous colitis and immune system activation in interleukin-10-deficient mice. Infect Immun 66 (1998) 5224-5231
153. Kado S., Uchida K., Funabashi H., et al. Intestinal microflora are necessary for development of spontaneous adenocarcinoma of the large intestine in T-cell receptor beta chain and p53 double-knockout mice. Cancer Res 61 (2001) 2395-2398
154. Engle S.J., Ormsby I., Pawlowski S., et al. Elimination of colon cancer in germ-free transforming growth factor beta 1-deficient mice. Cancer Res 62 (2002) 6362-6366
155. Chu F.F., Esworthy R.S., Chu P.G., et al. Bacteria-induced intestinal cancer in mice with disrupted Gpx1 and Gpx2 genes. Cancer Res 64 (2004) 962-968
156. Van der Sluis M., De Koning B.A., De Bruijn A.C., et al. Muc2-deficient mice spontaneously develop colitis, indicating that MUC2 is critical for colonic protection. Gastroenterology 131 (2006) 117-129
157. Velcich A., Yang W., Heyer J., et al. Colorectal cancer in mice genetically deficient in the mucin Muc2. Science 295 (2002) 1726-1729
158. Rudolph U., Finegold M.J., Rich S.S., et al. Ulcerative colitis and adenocarcinoma of the colon in G alpha i2-deficient mice. Nat Genet 10 (1995) 143-150
159. Kohonen-Corish M.R., Daniel J.J., te Riele H., et al. Susceptibility of Msh2-deficient mice to inflammation-associated colorectal tumors. Cancer Res 62 (2002) 2092-2097
160. Greten F.R., Eckmann L., Greten T.F., et al. IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 118 (2004) 285-296
161. Kobayashi K.S., Chamaillard M., Ogura Y., et al. Nod2-dependent regulation of innate and adaptive immunity in the intestinal tract. Science 307 (2005) 731-734
162. Maeda S., Hsu L.C., Liu H., et al. Nod2 mutation in Crohn's disease potentiates NF-kappaB activity and IL-1beta processing. Science 307 (2005) 734-738
163. Fukata M., Chen A., Vamadevan A.S., et al. Toll-like receptor-4 promotes the development of colitis-associated colorectal tumors. Gastroenterology 133 (2007) 1869-1881
164. Popivanova B.K., Kitamura K., Wu Y., et al. Blocking TNF-alpha in mice reduces colorectal carcinogenesis associated with chronic colitis. J Clin Invest 118 (2008) 560-570
165. Zhu Y., Richardson J.A., Parada L.F., et al. Smad3 mutant mice develop metastatic colorectal cancer. Cell 94 (1998) 703-714
166. Yang X., Letterio J.J., Lechleider R.J., et al. Targeted disruption of SMAD3 results in impaired mucosal immunity and diminished T cell responsiveness to TGF-b. EMBO J 18 (1999) 1280-1291
167. Datto M.B., Frederick J.P., Pan L., et al. Targeted disruption of Smad3 reveals an essential role in transforming growth factorβ-mediated signal transduction. Mol Cell Biol 19 (1999) 2495-2504
168. Maggio-Price L., Treuting P., Zeng W., et al. Helicobacter infection is required for inflammation and colon cancer in Smad3-deficient mice. Cancer Res 66 (2006) 828-838
169. Bohr U.R., Selgrad M., Ochmann C., et al. Prevalence and spread of enterohepatic Helicobacter species in mice reared in a specific-pathogen-free animal facility. J Clin Microbiol 44 (2006) 738-742
170. Kobaek-Larsen M., Thorup I., Diederichsen A., et al. Review of colorectal cancer and its metastasis in rodent models: comparative aspects with those in humans. Comp Med 50 (2000) 16-26
171. Heijstek M.W., Kranenburg O., and Borel Rinkes I.H.M. Mouse models of colorectal cancer and liver metastasis. Dig Surg 22 (2005) 16-25
172. Alencar H., King R., Fiunovics M., et al. A novel mouse model for segmental orthotopic colon cancer. Int J Cancer 117 (2005) 335-339
173. Céspedes M.V., Espina C., Garcia-Cabezas M.A., et al. Orthotopic microinjection of human colon cancer cells in nude mice induces tumor foci in all clinically relevant metastatic sites. Am J Pathol 170 (2007) 1077-1085
174. Tsutsumi S., Kuwano H., Morinaga N., et al. Animal model of para-aortic lymph node metastasis. Cancer Lett 169 (2001) 77-85
175. Sun F.X., Sasson A.R., Jiang P., et al. An ultra-metastatic model of human colon cancer in nude mice. Clin Exp Metastasis 17 (1999) 41-48
176. Thalheimer A., Illert B., Beuter M., et al. Feasibility and limits of an orthotopic human colon cancer model in nude mice. Comp Med 56 (2006) 105-109
177. Corbett T.H., Griswold Jr. D.P., Roberts B.J., et al. Tumor induction relationships in development of transplantable cancers of the colon in mice for chemotherapy assays, with a note on carcinogen structure. Cancer Res 35 (1975) 2434-2439
178. Franks L.M., and Hemmings V.J. A cell line from an induced carcinoma of mouse rectum. J Pathol 124 (1978) 35-38
179. 2 gene. J Biol Chem 275 (2000) 34013-34016
180. Nakanishi M., Montrose D.C., Clark P., et al. Genetic deletion of mPGES-1 suppresses intestinal tumorigenesis. Cancer Res 68 (2008) 3251-3259
181. Min mice. Cancer Res 67 (2007) 881-889
182. Clarke A.R., Cummings M.C., and Harrison D.J. Interaction between murine germline mutations in p53 and APC predisposes to pancreatic neoplasia but not to increased intestinal malignancy. Oncogene 11 (1995) 1913-1920
183. Heppner Goss K., Risinger M.A., Kordich J.J., et al. Enhanced tumor formation in mice heterozygous for Blm mutation. Science 297 (2002) 2051-2053
184. Rudolph K.L., Millard M., Bosenberg M.W., et al. Telomere dysfunction and evolution of intestinal carcinoma in mice and humans. Nat Genet 28 (2001) 155-159
185. WAF/cip1 gene enhances Apc-initiated tumor formation and the tumor-promoting activity of a western-style high-risk diet by altering cell maturation in the intestinal mucosa. Cancer Res 61 (2001) 565-569
186. Philipp-Staheli J., Kim K.-H., Payne S.R., et al. Pathway-specific tumor suppression: reduction of p27 accelerates gastrointestinal tumorigenesis in Apc mutant mice, but not in Smad3 mutant mice. Cancer Cell 1 (2002) 355-368
187. Wilson C.L., Heppner K.J., Labovsky P.A., et al. Intestinal tumorigenesis is suppressed in mice lacking the metalloproteinase matrilysin. Proc Natl Acad Sci U S A 94 (1997) 1402-1407
188. Yang W., Bancroft L., Liang J., et al. p27kip1 in intestinal tumorigenesis and chemoprevention in the mouse. Cancer Res 65 (2005) 9363-9368
189. Ahn B., and Oshima H. Suppression of intestinal polyposis in (ApcMin/+) mice by inhibiting nitric oxide production. Cancer Res 61 (2001) 8357-8360
190. Laird P.W., Jackson-Grusby L., Faseli A., et al. Suppression of intestinal neoplasia by DNA hypomethylation. Cell 81 (1995) 197-205
191. Sansom W.J., Berger J., Bishop S.M., et al. Deficiency of Mbd2 suppresses intestinal tumorigenesis. Nat Genet 34 (2003) 145-147
192. Wong E., Yang K., Kuraguchi M., et al. Mbd4 inactivation increases Cright-arrowT transition mutations and promotes gastrointestinal tumor formation. Proc Natl Acad Sci U S A 99 (2002) 14937-14942
193. Millar C.B., Guy J., Sansom O.J., et al. Enhanced CpG mutability and tumorigenesis in MBD4-deficient mice. Science 297 (2002) 403-405
194. Min/+ mice. Cancer Res 63 (2003) 895-901
195. Schaetzlein S., Kodandaramireddy N.R., Ju Z., et al. Exonuclease-1 deletion impairs DNA damage signaling and prolongs lifespan of telomere-dysfunctional mice. Cell 130 (2007) 863-877
196. Shibata H., Toyama K., Shioya H., et al. Rapid colorectal adenoma formation initiated by conditional targeting of the Apc gene. Science 278 (1997) 120-123